The regulator record on finasteride, in order and dated

Almost every claim made about finasteride online is undated. That is what makes the subject so hard to read: a 2012 opinion and a 2026 regulatory decision arrive looking identical. This page puts the documents in order and says what each one actually changed.

1992 and 1997: two approvals, one molecule

The FDA approved the higher-strength tablet for an enlarged prostate on 19 June 1992, and the lower-strength tablet for male pattern hair loss in men on 19 December 1997. Both dates are stated in the FDA's own compounding alert of 2025, which is a convenient place to find them quoted by the agency itself.

That split is the origin of half the confusion in this subject. One molecule, two licences, two populations — young men keeping their hair and older men with urinary symptoms — and safety data that gets quoted across the boundary in both directions.

2016: a regulator uses the name

New Zealand's Medsafe published "Post-Finasteride Syndrome" in its Prescriber Update in March 2016, describing sexual, physical and neuropsychiatric symptoms that often persist after stopping, and telling prescribers to raise them before treatment begins. It changed no label. Its significance is that a national regulator was willing to print the term at all — and the page now carries Medsafe's own notice that it is more than five years old.

November 2023: the current US labelling

The FDA-approved labelling for the hair-loss tablet was last revised in November 2023. Its post-approval section lists sexual dysfunction that continued after discontinuation, male infertility and poor semen quality, male breast cancer, and depression and suicidal ideation and behaviour — each with the standing caveat that frequency cannot be reliably estimated from voluntary reports.

The label is also where the benefit figures live: the five-year photograph panel, the hair counts, and the year-one adverse-experience table. The side-effect record separates those figures by what kind of evidence each is, and the medicine itself is described in full on its own page.

29 April 2024: the UK puts a card in the pack

The MHRA's Drug Safety Update on 29 April 2024 did three things. It reminded prescribers that finasteride is associated with depression, suicidal thoughts and sexual dysfunction, and that patients have reported sexual dysfunction persisting after treatment stopped. It told prescribers to ask about a history of depression or suicidal ideation first, and to monitor for both kinds of effect. And it introduced a patient card into every pack.

Its own reasoning is the interesting part. The agency noted it had issued an update on finasteride in 2017, but that at the time the potential for persistence was not widely known. The 2024 action was about awareness, not about new science.

22 April 2025: the FDA on compounded topicals

The FDA published a compounding risk alert stating that there is no FDA-approved topical formulation of finasteride, that absorption through the skin into the bloodstream is expected, and that it had received 32 reports of adverse events associated with compounded topical finasteride between 2019 and 2024. The reported events resembled those seen with the oral drug, and most of the reports said the events continued to persist after the product was stopped.

It also names a risk specific to a cream or spray: transfer to other people, particularly women, since compounded topicals have none of the coating that stops skin contact with a tablet. Topical finasteride has its own page, because the regulatory picture differs sharply between countries.

19 June and 22 August 2025: the EU decides

A review begun at the request of the French medicines agency ran through the Pharmacovigilance Risk Assessment Committee, was endorsed by the coordination group on 19 June 2025, and became a binding European Commission decision on 22 August 2025. Suicidal ideation was confirmed as a side effect of finasteride tablets at an unknown frequency; a patient card was mandated for the hair-loss packs across the EU; and the product information was extended to say that problems with sexual function may contribute to mood changes.

Two negative findings in the same decision deserve as much attention as the positive one. The review found no evidence linking suicidal ideation to finasteride skin sprays, and it found insufficient evidence to establish a causal association for dutasteride — adding a warning to dutasteride anyway, as a precaution, on the basis of a possible class effect.

11 May 2026: the UK tightens again

The most recent document is the MHRA's Drug Safety Update of 11 May 2026, which followed a further review of the European referral, UK reports and other regulators' actions. Product information for the hair-loss tablet is being updated with a warning that sexual dysfunction may contribute to mood disorders, and that sexual dysfunction has also been reported without mood alterations. Dutasteride gains a precautionary note that depressed mood, depression or suicidal ideation has been reported with another medicine of the same class.

The UK's Yellow Card totals to 31 May 2025, given in that update: 170 reports of suicidal ideation and related terms for finasteride, of which 19 were fatal reports of suicide, and 5 reports for dutasteride with no fatal reports. The update states the standing caveat itself — that a reported reaction does not necessarily mean the medicine caused it.

The 2017 update nobody remembers

There is a ninth document, and the MHRA raises it itself. It issued a Drug Safety Update on finasteride in 2017 — and then wrote, in 2024, that at the time the potential for persistence of some of the side effects was not widely known.

That sentence is a regulator marking its own homework in public, and it is the strongest evidence on this page that the system moves slowly rather than that it hides things. A warning existed. It did not land. Seven years later the same agency put a card in the box.

How to check any claim about this drug yourself

The method is dull and it works on almost any medicine, not just this one.

1. Ask what document the claim comes from and when it was published. If there is no answer, stop there — most of the confident writing on this subject fails at this step.
2. Go to the regulator, not to a site quoting the regulator. Labels are on DailyMed; UK safety bulletins are on gov.uk under Drug Safety Update; European reviews are on the EMA site under referrals.
3. Read which product the document is about. A finding about the prostate tablet at five times the strength is not a finding about the hair-loss tablet, and a finding about a licensed spray is not a finding about a compounded cream.
4. Check whether a figure is from a controlled trial or from spontaneous reports. The first can support a rate; the second cannot, and says so in its own preamble.

What the sequence shows

Read as a run rather than as quotes, the record has a shape. Nothing dramatic happened to the evidence between 2024 and 2026. What changed is that three regulators independently concluded that information already sitting in the product literature was not reaching the people it was written for, and each of them moved it closer to the patient: into a card in the pack, into a warning on the leaflet, into an instruction to ask about mood before prescribing.

That is not a cover-up and it is not an exoneration. It is a system correcting a communication failure, slowly, in public, with the dates attached. What is still contested is a separate question, and the regulators are careful about it for good reason.